CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$55.65 USD
-0.76 (-1.35%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $55.13 -0.52 (-0.93%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -153.61 | -650.18 | 377.66 | -348.87 | 66.86 |
Depreciation/Amortization & Depletion | 19.84 | 24.17 | 32.06 | 9.18 | 4.73 |
Net Change from Assets/Liabilities | -193.59 | 19.85 | 26.86 | 33.44 | -48.43 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 66.98 | 110.42 | 102.39 | 67.88 | 33.52 |
Net Cash From Operating Activities | -260.38 | -495.74 | 538.97 | -238.37 | 56.68 |
Property & Equipment | -9.47 | -37.19 | -81.71 | -18.36 | -6.68 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 386.62 | -221.47 | -953.73 | -522.81 | 0.00 |
Other Investing Activities | -2.50 | 0.00 | 0.00 | 0.00 | 8.01 |
Net Cash from Investing Activities | 374.65 | -258.66 | -1,035.43 | -541.17 | 1.33 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 62.66 | 38.59 | 250.95 | 1,016.15 | 430.98 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 62.66 | 38.59 | 250.95 | 1,016.15 | 430.98 |
Effect of Exchange Rate Changes | 0.07 | -0.08 | -0.01 | 0.04 | 0.02 |
Net Change In Cash & Equivalents | 177.01 | -715.88 | -245.52 | 236.66 | 489.00 |
Cash at Beginning of Period | 224.06 | 939.94 | 1,185.47 | 948.81 | 459.81 |
Cash at End of Period | 401.07 | 224.06 | 939.94 | 1,185.47 | 948.81 |
Diluted Net EPS | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 |
Fiscal Year End for CRISPR Therapeutics AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -153.61 | -242.96 | -130.81 | -53.07 |
Depreciation/Amortization & Depletion | NA | 19.84 | 14.94 | 10.01 | 5.05 |
Net Change from Assets/Liabilities | NA | -193.59 | 10.39 | -42.17 | 36.91 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 66.98 | 53.33 | 38.52 | 19.91 |
Net Cash From Operating Activities | NA | -260.38 | -164.30 | -124.45 | 8.80 |
Property & Equipment | NA | -9.47 | -8.73 | -6.61 | -3.06 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 386.62 | 467.33 | 342.87 | 120.89 |
Other Investing Activities | NA | -2.50 | -2.50 | -1.50 | 0.00 |
Net Cash from Investing Activities | NA | 374.65 | 456.10 | 334.75 | 117.83 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 62.66 | 23.73 | 22.17 | 5.40 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 62.66 | 23.73 | 22.17 | 5.40 |
Effect of Exchange Rate Changes | NA | 0.07 | 0.01 | 0.06 | 0.03 |
Net Change In Cash & Equivalents | NA | 177.01 | 315.54 | 232.54 | 132.06 |
Cash at Beginning of Period | NA | 224.06 | 224.06 | 224.06 | 224.06 |
Cash at End of Period | NA | 401.07 | 539.60 | 456.60 | 356.12 |
Diluted Net EPS | NA | 1.12 | -1.41 | -0.98 | -0.67 |